If selected for SBIR funding, the SBC will be granted a royalty - free,
non-exclusive internal research - use license for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.
Caribou granted Novartis an option for a
non-exclusive, worldwide license for
internal research under Caribou's CRISPR - Cas9 technology in 2014 as part of a one - year
research program to develop the Caribou CRISPR - Cas9 platform for drug target screening and validation technologies, and Novartis exercised its option for an
internal research license in 2016.